



SpineSmith Partners, LP to Present at the 3rd Annual Stem Cell Summit, in New York City

Contact: Keri Kimler
kkimler@spinesmithusa.com
512.206.0770

Austin, TX – February 25, 2008 — SpineSmith Partners, LP, a biotech medical device company that focuses on new treatments for spinal disorders, announced today that Dr. Robert G. Johnson, MD, and Dr. Stuart Williams, PhD, are scheduled to present at the 3rd Annual Stem Cell Summit in New York City on Tuesday, Feb. 26, 2008.

Dr. Williams is Scientific Director of the Cardiovascular Innovation Institute at the University of Louisville School of Medicine. He is also the Chief Science Officer for Tissue Genesis, Inc.

Williams is recognized internationally as an expert in vascular biology and vascular tissue engineering, and is a leader in endothelial cell isolation technology. He developed and patented the technique of isolating human endothelial cells and pluripotent stem cells from fat tissue obtained through liposuctions, currently licensed by Tissue Genesis through Thomas Jefferson University.

Dr. Johnson, a San Antonio, Texas-based orthopedic surgeon is pioneering a new technology utilizing highly concentrated adult stem cells in spine surgery. With over 300 cases performed and a prospective clinical study showing positive results, Dr. Johnson believes that adult stem cells have a place in spine surgery and further applications throughout orthopedics.

Dr. Johnson has been using the new approach to treat patients since April 2006. The adult stem cells are concentrated from the patient's own bone marrow utilizing a point of care system during the spinal procedure.

- more -

“It is already well known that stem cells originating from bone marrow have the capability to form blood, nerve and bones. The goal is to help patients recover faster and, hopefully, better,” said Dr. Johnson. “We have good reason to be optimistic that the stem cells will provide reliable and consistent fusion and reduce the chances that the patient will require future surgeries.”

Since autologous procedures use the patient's own cells, derived from bone marrow or adipose (fat) tissue, the likelihood of rejection of a foreign tissue or synthetic substance is no longer a concern.

The Annual Stem Cell Summit brings together industry leaders, scientists, corporate executives, investment firms, practitioners and research institutions throughout the world. This year's Summit will feature more than 50 speakers discussing the most cutting edge technologies and innovations in all applications of stem cell therapies. Additional information about the 3rd Annual Stem Cell Summit is available at www.stemcellsummit.com.

About SpineSmith Partners, LP

SpineSmith, LP, (www.spinesmithusa.com) designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. We take a different approach from other companies, utilizing a collaborative approach between scientists, engineers and spine surgeons. This approach results in the development of truly innovative biological and hardware technologies for use in the treatment of patients with spinal disorders. Our unique, think-tank approach gives spine surgeons the ability to directly impact the direction of our product portfolio, ensuring applicability and achieving the highest standards of patient care.

About the 3rd Annual Stem Cell Summit

The Annual Stem Cell Summit is organized and produced by RRY Publications and Robin Young Consulting. This year's Summit is slated to bring together investors, industry executives, practitioners and analysts to learn about the investment opportunities in the stem cell marketplace, the groundbreaking stem cell products physicians are using today and the growing market potential in terms of revenues. For additional information or to register, please visit www.stemcellsummit.com.

SOURCE: SpineSmith Partners, LP, 8140 N. Mopac, Building II, Suite 120, Austin, TX 78759

###